TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer

- Collaboration provides support for platform and funding to support development of safer, more-specific ADCs on up to three cancer targets -

SAN FRANCISCO, Sept. 23, 2025 /PRNewswire/ -- TegMine Therapeutics, Inc., ("TegMine"), a biotechnology company focused on redefining precision oncology by targeting the glycoproteins that drive cancer, today announced a strategic research and development collaboration with Boehringer Ingelheim. The partnership will leverage TegMine's proprietary 2-Factor Antibody System to develop more selective and better-tolerated ADC therapeutics.

The collaboration is centered on an initial program targeting a clinically validated antigen, with the potential to expand to two additional targets. Powered by its proprietary TegMiner™ platform, TegMine discovers novel, tumor-specific glycan epitopes that are invisible to conventional approaches. The company's 2-Factor Antibody System delivers a new level of therapeutic precision, requiring dual glycan/protein-based recognition to achieve unprecedented specificity and enhanced efficacy, with a goal to reduce on-target, off-tumor toxicity for the benefit of patient safety.

"At TegMine, we are exploiting the unique biology of tumor-associated glycans, molecular signatures that are highly prevalent in aggressive solid tumors yet largely absent in healthy tissues," said Jeff Bernstein, Ph.D., CEO of TegMine. "This collaboration endorses our approach, and specifically our 2-Factor Antibody System, which unlocks specific tumor-associated antigens and targets that were previously inaccessible with other technologies. We are excited to translate this approach into potentially meaningful therapies for patients alongside a world-class partner in Boehringer Ingelheim."

Under the terms of the agreement, TegMine will receive an upfront payment and research funding per target as well as a target option fee for each selected additional target. The company is also eligible to receive preclinical, clinical, regulatory, and commercial milestones, along with royalties on net sales for any potential products developed under the collaboration. Exact financial terms are undisclosed. Boehringer Ingelheim has global development and commercial rights for each target generated during the collaboration.

About TegMine Therapeutics

TegMine is redefining precision oncology by targeting highly expressed glycans that drive cancer aggressiveness and immune evasion. Our mission is to eradicate cancer by identifying unique tumor antigens that are consistently prevalent across the tumor while being largely absent from healthy tissues. Our platform is designed to generate antibodies that deliver the greatest therapeutic impact, which is adaptable across numerous treatment modalities.

For more information, please visit https://tegminetx.com and engage with us on social.

Contacts:
TegMine

Jeff Bernstein - CEO
[email protected]

SOURCE TegMine Therapeutics